Educational information, not financial advice or a personal recommendation. Not regulated by the FCA. Do your own research. Capital at risk.
Sterling AlmanacExploreStart hereFind your fitGlossaryCompareMy ListMy PieEarnings calendarSupport

BioNTech SE (BNTX)

Healthcare Out of favour

BioNTech is a German biotechnology firm that uses messenger RNA technology to develop innovative treatments for cancer and infectious diseases.

$90.58

Is BioNTech SE a good stock for a UK beginner?

The honest version: BioNTech is a German biotechnology firm that uses messenger RNA technology to develop innovative treatments for cancer and infectious diseases.

No rating · no target price · nothing for sale here
Price+12.3%
Priced in USD - as a UK investor your £ return also moves with the pound-to-dollar exchange rate, on top of the share price itself.
52-week range-16% past year
$90.58
Low $79.52High $124.00
Where today's price sits versus its past year - context, not a signal.
If you had put $1,000 into BioNTech SE
$1,123+12%

Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.

Market cap: The company's total value on the stock market - share price times the number of shares. Big = 'large-cap', small = 'small-cap'.
$22.91B
Avg volume: How many shares change hands on a typical day. Higher means it's easy to buy or exit without moving the price.
926.81K
Day range: The lowest and highest price the shares traded at during the latest day.
$90.45 – $93.04
52-week range: The lowest and highest the shares have traded over the past year - a sense of how wide the swings have been.
$79.52 – $124.00
Dividend yield: The yearly dividend as a percentage of the share price - roughly the income you'd earn from dividends alone.
0.0%
Beta: How bumpy the share price is versus the whole market. Above 1 swings more than the market; below 1 is calmer. It's about the ride, not whether it goes up or down.
1.32
How bumpy is it?Beta: How bumpy the share price is versus the whole market. Above 1 swings more than the market; below 1 is calmer. It's about the ride, not whether it goes up or down. 1.32
Calm
Wild
Bumpier than the market

Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.

Why has it been moving?▼ -1% past week · ▼ -16% past year

Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.

The bull case

Breakthrough in mRNA cancer therapy commercialisation

The bear case

Inability to turn research into profitable products

What does BioNTech SE do?

Best known for its role in the COVID-19 vaccine, BioNTech is now pouring its resources into researching new ways to treat cancer using the same underlying technology. They make money primarily through vaccine sales, but they are currently spending heavily on research and development to build a pipeline of future medicines. Keep an eye on whether their experimental cancer treatments can pass clinical trials and reach the market.

VQGMI
Factor profile

On our factor screen it looks strongest on value and quality, and weakest on growth.

Value: How cheap the stock looks versus profits, sales and assets (higher = cheaper). 79Quality: How profitable and financially healthy the company is (higher = stronger). 49Growth: How fast revenue and earnings are growing (higher = faster). 1Momentum: How the share price has been trending recently (higher = stronger recent run). 24Income: The dividend income on offer and how sustainable it looks (higher = more/steadier). 16
Quick checks
What's strong
  • Value screens high (79/100)
  • Strong cash position from previous vaccine success
  • High gross margins indicate efficient production
  • Pioneering technology platform with broad potential
What to watch
  • Growth screens low (1/100)
  • Momentum screens low (24/100)
  • Income screens low (16/100)
  • High reliance on the success of experimental drugs
  • Clinical trials are expensive and often fail

What do BioNTech SE's numbers mean?

P/S
8.3
This compares the company's total market value to its annual sales, showing how much investors are paying for every pound of revenue generated.
P/B
1.1
This measures the share price against the company's net assets, suggesting the market is valuing the firm close to the accounting value of its physical and financial holdings.
Gross margin
78.7%
This shows that for every pound of revenue, the company keeps nearly 79 pence after accounting for the direct costs of producing its products.
Net margin
-44.6%
This indicates that the company is currently spending more on operations and research than it is bringing in through sales, resulting in a loss.

How much money does BioNTech SE make?

Revenue and profit by quarter, and how much of each sale turns into profit.

RevenueNet income
€0€379.73M€759.45M€1.14B€1.52BQ1 25Q2 25Q3 25Q4 25Q1 26
Gross margin
78.7%
Net margin
-44.6%
Return on equity
-6.7%

Does BioNTech SE pay a dividend?

No - BioNTech SE doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.

More in Healthcare

Eli LillyWest Pharmaceutical Services, Inc.Incyte CorporationThe Cigna GroupZimmer Biomet Holdings, Inc.Moderna, Inc.Gilead Sciences, Inc.Regeneron Pharmaceuticals, Inc.

What are the scenarios for BioNTech SE?

An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.

$122$91$69today · $91▲ Bull · $102• Base · $91▼ Bear · $77in 1 yearILLUSTRATIVE · NOT A PREDICTION OR PRICE TARGET
Bull
+10% to +15%Positive data from early-stage cancer clinical trials
Base
-5% to +5%Steady operational progress with no major news
Bear
-10% to -20%Further decline in vaccine demand and rising costs

What are the pros and cons of BioNTech SE?

3bull points
6bear points

How many points the write-up makes each way — a balance check, not a score or verdict.

The bull case3
  • Strong cash position from previous vaccine success
  • High gross margins indicate efficient production
  • Pioneering technology platform with broad potential
The catch3
  • Significant decline in revenue as pandemic demand fades
  • Currently operating at a loss due to high research spending
  • No dividend payments for shareholders
Key risks3
  • High reliance on the success of experimental drugs
  • Clinical trials are expensive and often fail
  • High volatility compared to the broader market
What would flip the thesis

The write-up's own warning lights — if these start happening, the case above changes.

Confidence: medium · data: USD · flags: pe, earnings_growth · Charts by TradingView Lightweight Charts™
Found this useful? The Almanac is free and ad-free - a coffee keeps it that way.Support →

Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →

This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.

Figures as of 2026-08-01. Prices may be delayed and numbers can go stale - always double-check before acting.